Enhancing soluble expression and purification of a bispecific scFv antibody in Escherichia coli using chaperones

Zahra Alidousti-Shahraki , Afrooz Amini-Dehkordi, Nafiseh Esmaeil, Vajihe Akbari

Abstract


Background and purpose: The use of a bispecific antibody engineered as a tandem single-chain fragment variable antibody (scFv-BsAb) offers several advantages over full-length antibodies, including enhanced tissue penetration and the potential for production in bacterial cells. However, production of them in bacteria usually results in the formation of inclusion bodies. The current work aimed to facilitate proper folding and soluble expression of a recombinant scFv-BsAb targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) by co-expression with molecular chaperones.

Experimental approach: Escherichia coli BL21(DE3) cells harboring pET28a-scFv-BsAb and pKJE7 plasmids were used as host cells for protein expression. The effect of different temperatures and IPTG concentrations on the expression of soluble protein with or without expression of chaperones was investigated by SDS-PAGE and densitometry analysis. Subsequently, the expressed protein was subjected to native purification using a Ni-NTA affinity column. Then, the binding ability of the scFv-BsAb to the receptors on peripheral blood mononuclear cells (PBMCs) was evaluated by flow cytometry.

Findings/Results: Co-expression with chaperones slightly enhanced the expression of soluble scFv-BsAb. The optimal condition for soluble expression of protein is at a temperature of 30 °C and an IPTG concentration of 1 mM when co-expressed with chaperones. The final yield of protein in co-expression with chaperones was 2.9 mg protein per 1 L of culture.

Conclusion and implications: Optimization of culture conditions and co-expression with molecular chaperones may be useful for the production of soluble and functionally bioactive scFv antibodies in E. coli.

 


Keywords


Bispecific antibody; Immune checkpoint inhibitors; Molecular chaperones; Single-chain antibodies; Soluble expression.

Full Text:

PDF

References


Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies (Basel). 2020;9(3):34,1-20.DOI: 10.3390/antib9030034.

Kumar AR, Devan AR, Nair B, Vinod BS, Nath LR. Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. Mol Biol Rep. 2021;48(12):8075-8095.DOI: 10.1007/s11033-021-06752-9.

Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297-339.DOI: 10.1016/S0065-2776(06)90008-X.

Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 2018;11(1):31,1-26.DOI: 10.1186/s13045-018-0578-4.

Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y, et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther. 2022;7(1):39,1-28.DOI: 10.1038/s41392-021-00868-x.

Li H, Er Saw P, Song E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol. 2020;17(5): 451-461.DOI: 10.1038/s41423-020-0417-8.

Nelson AL. Antibody fragments. mAbs. 2010;2(1):77-83.DOI: 10.4161/mabs.2.1.10786.

Paerhati P, Jakos T, Bai SY, Zhu JW, Yuan YS. Strategies and applications of antigen-binding fragment (Fab) production in Escherichia coli. Pharm Fronts. 2021;3(2):e39-e49.DOI: 10.1055/s-0041-1735145.

Rashti A, Akbari V. Construction and periplasmic expression of a bispecific tandem scFv for dual targeting of immune checkpoints. Adv Biomed Res. 2023;12:42,1-5.DOI: 10.4103/abr.abr_31_22.

Kipriyanov SM. High-level periplasmic expression and purification of scFvs. Methods Mol Biol. 2009:562:205-214.DOI: 10.1007/978-1-60327-302-2_16.

Tungekar AA, Ruddock LW. Design of an alternate antibody fragment format that can be produced in the cytoplasm of Escherichia coli. Sci Rep. 2023;13(1):14188,1-10.DOI: 10.1038/s41598-023-41525-3.

Gaciarz A, Veijola J, Uchida Y, Saaranen MJ, Wang C, Hörkkö S, et al. Systematic screening of soluble expression of antibody fragments in the cytoplasm of E. coli. Microb Cell Fact. 2016;15:22. DOI: 10.1186/s12934-016-0419-5.

Guglielmi L, Martineau P. Expression of single-chain Fv fragments in E. coli cytoplasm. Methods Mol Biol. 2009;562:215-224.DOI: 10.1007/978-1-60327-302-2_17.

Mamipour M, Yousefi M, Hasanzadeh M. An overview on molecular chaperones enhancing solubility of expressed recombinant proteins with correct folding. Int J Biol Macromol. 2017;102:367-375.DOI: 10.1016/j.ijbiomac.2017.04.025.

de Marco A. Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli. Microb Cell Fact. 2009;8:26,1-18.DOI: 10.1186/1475-2859-8-26.

Kravats AN, Wickner S, Camberg JL. Molecular Chaperones. Reference Module in Life Sciences: Elsevier; 2022.

Hayer-Hartl M, Bracher A, Hartl FU. The GroEL–GroES chaperonin machine:a nano-cage for protein folding. Trends Biochem Sci. 2016;41(1):62-76.DOI: 10.1016/j.tibs.2015.07.009.

Ziemienowicz A, Skowyra D, Zeilstra-Ryalls J, Fayet O, Georgopoulos C, Zylicz M. Both the Escherichia coli chaperone systems, GroEL/GroES and DnaK/DnaJ/GrpE, can reactivate heat-treated RNA polymerase. Different mechanisms for the same activity. J Biol Chem. 1993;268(34):25425-25431.PMID: 7902351.

Sandomenico A, Sivaccumar JP, Ruvo M. Evolution of Escherichia coli expression system in producing antibody recombinant fragments. Int J Mol Sci. 2020;21(17):6324,1-39.DOI: 10.3390/ijms21176324.

Mirzapour Estabragh A, Sadeghi HMM, Akbari V. Co-expression of chaperones for improvement of soluble expression and purification of an anti-HER2 scFv in Escherichia coli. Adv Biomed Res. 2022;11:117,1-6.

DOI: 10.4103/abr.abr_351_21.

Saibil H. Chaperone machines for protein folding, unfolding and disaggregation. Nat Rev Mol Cell Biol. 2013;14(10):630-642.DOI: 10.1038/nrm3658.

Mierendorf R, Yeager K, Novy R. The pET system:your choice for expression. Innovations. 1994;1(1):1-3.

Soheili S, Jahanian-Najafabadi A, Akbari V. Evaluation of soluble expression of recombinant granulocyte macrophage stimulating factor (rGM-CSF) by three different E. coli strains. Res Pharm Sci. 2020;15(3):218-225.DOI: 10.4103/1735-5362.288424.

Akbari V, Sadeghi HM, Jafarian-Dehkordi A, Chou CP, Abedi D. Optimization of a single-chain antibody fragment overexpression in Escherichia coli using response surface methodology. Res Pharm Sci. 2015;10(1):75-83.PMID: 26430460.

Roufarshbaf M, Esmaeil N, Akbari V. Comparison of four methods of colon cancer cell lysates preparation for ex vivo maturation of dendritic cells. Res Pharm Sci. 2021;17(1):43-52.DOI: 10.4103/1735-5362.329925.

Muñoz-López P, Ribas-Aparicio RM, Becerra-Báez EI, Fraga-Pérez K, Flores-Martínez LF, Mateos-Chávez AA, et al. Single-chain fragment variable:recent progress in cancer diagnosis and therapy. Cancers (Basel). 2022;14(17): 4206,1-26.DOI: 10.3390/cancers14174206.

Bhatwa A, Wang W, Hassan YI, Abraham N, Li XZ, Zhou T. Challenges associated with the formation of recombinant protein inclusion bodies in Escherichia coli and strategies to address them for industrial applications. Front Bioeng Biotechnol. 2021;9:630551,1-18.DOI: 10.3389/fbioe. 2021.630551.

Yousefi M, Farajnia S, Mokhtarzadeh A, Akbari B, Ahdi Khosroshahi S, Mamipour M, et al. Soluble expression of humanized anti-CD20 single-chain antibody in Escherichia coli by cytoplasmic chaperones co-expression. Avicenna J Med Biotechnol. 2018;10(3):141-146.PMID: 30090206.

Sun XW, Wang XH, Yao YB. Co-expression of Dsb proteins enables soluble expression of a single-chain variable fragment (scFv) against human type 1 insulin-like growth factor receptor (IGF-1R) in E. coli. World J Microbiol Biotechnol. 2014;30(12):3221-3227.DOI: 10.1007/s11274-014-1749-2.

Utami DF, Azizah MI, Sriwidodo S, Haryanto RA, Pratiwi RD, Maksum IP. Effect of co-expression chaperones on the expression of intracellular recombinant proteins in Escherichia coli. Chim Nat Acta. 2023;11(2):25-33.DOI: 10.24198/cna.v11.n2.46480.

Fatima K, Naqvi F, Younas H. A review: molecular chaperone-mediated folding, unfolding and disaggregation of expressed recombinant proteins. Cell Biochem Biophys. 2021;79:153-174.DOI: 10.1007/s12013-021-00970-5.

Francis DM, Page R. Strategies to optimize protein expression in E. coli. Curr Protoc Protein Sci. 2010;5(1):5.24.1-5.24.29.DOI: 10.1002/0471140864.ps0524s61.

Shishparenok AN, Gladilina YA, Zhdanov DD. Engineering and expression strategies for optimization of L-asparaginase development and production. Int J Mol Sci. 2023;24(20): 15220,1-60.DOI: 10.3390/ijms242015220.

Judge SJ, Dunai C, Sturgill IR, Stoffel KM, Murphy WJ, Canter RJ. Assessment of PD-1 expression in human resting and activated natural killer cells and murine tumor models. J Clin Oncol. 2019;37(8 Suppl):36-36.DOI: 10.1200/JCO.2019.37.8_suppl.36.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.